CN104136612A - 特异性结合cgrp的核酸 - Google Patents

特异性结合cgrp的核酸 Download PDF

Info

Publication number
CN104136612A
CN104136612A CN201380009019.6A CN201380009019A CN104136612A CN 104136612 A CN104136612 A CN 104136612A CN 201380009019 A CN201380009019 A CN 201380009019A CN 104136612 A CN104136612 A CN 104136612A
Authority
CN
China
Prior art keywords
nucleic acid
acid molecule
seq
cgrp
nucleotide sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380009019.6A
Other languages
English (en)
Chinese (zh)
Inventor
S·舒尔兹臣
W·普尔施克
F·雅洛世
K·霍利戈
C·马什
S·克鲁斯曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TME Pharma AG
Original Assignee
Noxxon Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2012/000089 external-priority patent/WO2012095303A1/en
Application filed by Noxxon Pharma AG filed Critical Noxxon Pharma AG
Publication of CN104136612A publication Critical patent/CN104136612A/zh
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/16Aptamers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/34Spatial arrangement of the modifications
    • C12N2310/344Position-specific modifications, e.g. on every purine, at the 3'-end
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/35Nature of the modification
    • C12N2310/351Conjugate
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/10Applications; Uses in screening processes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Plant Pathology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201380009019.6A 2012-01-10 2013-01-10 特异性结合cgrp的核酸 Pending CN104136612A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP12000105.2 2012-01-10
EP12000105 2012-01-10
PCT/EP2012/000089 WO2012095303A1 (en) 2011-01-10 2012-01-10 Nucleic acid molecule having binding affinity to a target molecule and a method for generating the same
EPPCT/EP2012/000089 2012-01-10
PCT/EP2013/000055 WO2013104539A1 (en) 2012-01-10 2013-01-10 Nucleic acids specifically binding cgrp

Publications (1)

Publication Number Publication Date
CN104136612A true CN104136612A (zh) 2014-11-05

Family

ID=48781062

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380009019.6A Pending CN104136612A (zh) 2012-01-10 2013-01-10 特异性结合cgrp的核酸

Country Status (14)

Country Link
US (1) US9163243B2 (enrdf_load_stackoverflow)
EP (1) EP2802659A1 (enrdf_load_stackoverflow)
JP (1) JP2015506174A (enrdf_load_stackoverflow)
KR (1) KR20140111704A (enrdf_load_stackoverflow)
CN (1) CN104136612A (enrdf_load_stackoverflow)
AU (1) AU2013209130A1 (enrdf_load_stackoverflow)
BR (1) BR112014016939A2 (enrdf_load_stackoverflow)
CA (1) CA2860809A1 (enrdf_load_stackoverflow)
HK (1) HK1198370A1 (enrdf_load_stackoverflow)
IL (1) IL233515A0 (enrdf_load_stackoverflow)
MX (1) MX2014008456A (enrdf_load_stackoverflow)
RU (1) RU2014132706A (enrdf_load_stackoverflow)
SG (1) SG11201403769YA (enrdf_load_stackoverflow)
WO (1) WO2013104539A1 (enrdf_load_stackoverflow)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113383079A (zh) * 2018-11-12 2021-09-10 阿普塔里恩生物技术股份公司 Cxcl8结合性核酸

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2802660T (pt) 2012-01-10 2020-04-21 Aptarion Biotech Ag Novos ácidos nucleicos que se ligam a c5a
CN111973740A (zh) 2014-03-21 2020-11-24 泰华制药国际有限公司 针对降钙素基因相关肽的拮抗剂抗体及其使用方法
JP6584868B2 (ja) * 2015-02-25 2019-10-02 学校法人 関西大学 ゲル素材及びその製造方法
HK1258385A1 (zh) * 2015-09-24 2019-11-08 泰瓦制药国际有限公司 预防、治疗和减轻(持续性)创伤後头痛
ES2607639B1 (es) 2015-09-30 2018-02-28 Urquima, S.A Sal de ácido maleico de un intermedio de silodosina
SG10201913032TA (en) 2016-09-23 2020-02-27 Teva Pharmaceuticals Int Gmbh Treating refractory migraine

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060183700A1 (en) * 2002-05-06 2006-08-17 Noxxon Pharma Ag Cgrp binding nucleic acids
CN101217967A (zh) * 2005-05-04 2008-07-09 诺松制药股份公司 镜像异构体的新用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011020A (en) 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US5840867A (en) 1991-02-21 1998-11-24 Gilead Sciences, Inc. Aptamer analogs specific for biomolecules
US5582981A (en) 1991-08-14 1996-12-10 Gilead Sciences, Inc. Method for identifying an oligonucleotide aptamer specific for a target
US6682886B1 (en) 1994-04-28 2004-01-27 Gilead Sciences, Inc. Bivalent binding molecules of 7 transmembrane G protein-coupled receptors
EP0777684B1 (en) 1994-08-16 2004-04-28 Human Genome Sciences, Inc. Calcitonin receptor
WO1996038579A1 (en) 1995-06-02 1996-12-05 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to growth factors
US6395029B1 (en) 1999-01-19 2002-05-28 The Children's Hospital Of Philadelphia Sustained delivery of polyionic bioactive agents
US6652886B2 (en) 2001-02-16 2003-11-25 Expression Genetics Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents
RU2180311C1 (ru) 2001-07-05 2002-03-10 Мешалкин Георгий Алексеевич Защитная пробка
EP1306382A1 (de) 2001-10-26 2003-05-02 Noxxon Pharma AG Modifizierte L-Nukleinsäure
US7629456B2 (en) 2001-10-26 2009-12-08 Noxxon Pharma Ag Modified L-nucleic acid
WO2003070823A2 (en) 2002-02-20 2003-08-28 The General Hospital Corporation Conjugates comprising a biodegradable polymer and uses therefor
AU2004230927B9 (en) 2003-04-13 2011-12-01 Enzon Pharmaceuticals, Inc. Polymeric oligonucleotide prodrugs
GB0314472D0 (en) 2003-06-20 2003-07-23 Warwick Effect Polymers Ltd Polymer
CN1917905B (zh) 2004-02-09 2012-01-04 诺松制药股份公司 从多糖和多核苷酸生产缀合物的方法
DK1732607T3 (da) 2004-03-23 2019-07-22 Ascendis Pharma Gmbh Polymer-prodrug med en selvofrende linker
EP1807092B1 (en) 2004-11-05 2016-09-07 The Children's Hospital of Philadelphia Biodegradable linkers for molecular therapies
MX2009002859A (es) 2006-09-15 2009-03-30 Enzon Pharmaceuticals Inc Enlazadores biodegradables a base de ester impedido para suministro de oligonucleotidos.
US20100062436A1 (en) 2006-10-31 2010-03-11 Noxxon Pharma Ag Methods for Detection of a Single- or Double-Stranded Nucleic Acid Molecule
CN102906265B (zh) 2010-04-21 2016-08-24 诺松制药股份公司 脂质结合核酸
JP2014504865A (ja) * 2011-01-10 2014-02-27 ノクソン ファーマ エージー 標的分子との結合親和性を有する核酸分子およびその生成方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060183700A1 (en) * 2002-05-06 2006-08-17 Noxxon Pharma Ag Cgrp binding nucleic acids
CN101217967A (zh) * 2005-05-04 2008-07-09 诺松制药股份公司 镜像异构体的新用途

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DENEKAS ET AL.: "Inhibition of stimulated meningeal blood flow by a calcitonin gene-related peptide binding mirror-image RNA oligonucleotide", 《BRITISH JOURNAL OF PHARMACOLOGY》 *
EATON ET AL.: "Post-SELEX Combinatorial Optimization of Aptamers", 《BIOORGANIC & MEDICINAL CHEMISTRY》 *
JUHL ET AL.: "Effect of two novel CGRP-binding compounds in a closed cranial window rat model", 《EUROPEAN JOURNAL OF PHARMACOLOGY》 *
TREVINO ET AL.: "Evolution of functional nucleic acids in the presence of nonheritable backbone heterogeneity", 《PNAS》 *
VATER ET AL.: "Shot bioactive Spiegelmers to migraine-associated calcitonin gene-related peptide rapidly identified by a novel approach:Tailored-SELEX", 《NUCLEIC ACIDS RESEARCH》 *
杨晨等: "模拟乳腺癌骨转移微环境中CGRP对成骨细胞OPG和RANKL表达影响", 《中国肿瘤生物治疗杂志》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113383079A (zh) * 2018-11-12 2021-09-10 阿普塔里恩生物技术股份公司 Cxcl8结合性核酸
CN113383079B (zh) * 2018-11-12 2024-11-19 阿普塔里恩生物技术股份公司 Cxcl8结合性核酸

Also Published As

Publication number Publication date
RU2014132706A (ru) 2016-02-27
HK1198370A1 (en) 2015-04-10
CA2860809A1 (en) 2013-07-18
KR20140111704A (ko) 2014-09-19
WO2013104539A1 (en) 2013-07-18
SG11201403769YA (en) 2014-07-30
JP2015506174A (ja) 2015-03-02
IL233515A0 (en) 2014-08-31
EP2802659A1 (en) 2014-11-19
US9163243B2 (en) 2015-10-20
US20150031755A1 (en) 2015-01-29
BR112014016939A2 (pt) 2019-09-24
MX2014008456A (es) 2014-11-25
AU2013209130A1 (en) 2014-07-10

Similar Documents

Publication Publication Date Title
CN104136612A (zh) 特异性结合cgrp的核酸
KR102021626B1 (ko) Ngf에 대한 압타머 및 그의 용도
CN103339258A (zh) 具有对于靶分子的结合亲和力的核酸分子及产生所述核酸分子的方法
CN101189337A (zh) 生长素释放肽结合核酸
JP4823067B2 (ja) 生物活性グレリンに特異的に結合する核酸
CN103555725A (zh) Sdf-1结合性核酸
CN103958682A (zh) 结合胰高血糖素的核酸
CN101809154A (zh) C5a结合核酸
TWI500425B (zh) 對ngf之適體及其用途
JP4644599B2 (ja) グレリン結合核酸
EP3065744B1 (en) A ccl2 antagonist for use in treating proteinuria
WO2013082515A2 (en) Nucleic acid aptamers directed to surface receptors and methods of use
ES2368041T3 (es) Ácidos nucleicos de unión a ghrelina.
HK1130506B (en) Compounds and methods for peptide ribonucleic acid condensate particles for rna therapeutics
HK1184699B (en) Sdf-1 binding nucleic acids and the use thereof in cancer treatment

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20141105